Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity

Cancer

Volumn 92, Issue 10, 2001, Pages 2592-2602

  Damascelli, Bruno ^a   Cantuand̀, Giulio ^a   Mattavelli, Franco ^a,b,c   Tamplenizza, Paolo ^a   Bidoli, Paolo ^a   Leo, Ermanno ^a   Dosio, Franco ^a   Cerrotta, Anna M ^a   Tolla, Giuseppe Di ^a   Frigerio, Laura F ^a   Garbagnati, Francesco ^a   Lanocita, Rodolfo ^a   Marchianò, Alfonso ^a   Patelli, Gianluigi ^a   Spreafico, Carlo ^a   Tichà, Vladimira ^a   Vespro, Valentina ^c   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Intraarterial chemotherapy; Paclitaxel; Squamous cell carcinoma; Taxanes

Indexed keywords

ALBUMINOID; CASTOR OIL; CISPLATIN; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANUS CARCINOMA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CATHETERIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; EYE TOXICITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEMIPARESIS; HUMAN; IN VITRO STUDY; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PARTICLE SIZE; SURFACE-ACTIVE AGENTS; TREATMENT OUTCOME;

EID: 0035889882     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4     Document Type: Article

References (28)

1. Methods for preventing reactions secondary to Cremophor EL
2. Hypersensitivity reactions from taxol
3. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: An in vitro study
4. Paclitaxel hypersensitivity reactions. A role for docetaxel substitution
5. Recurrent squamous-cell lung cancer treated with bronchial-arterial infusion of docetaxel. Case report
6. A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel
7. Paclitaxel (taxol) for the treatment of head and neck cancer
8. Docetaxel, an active drug for squamous cell carcinoma of the neck
9. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin for curable, locally advanced squamous cell cancer of the head and neck
10. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma. Current and future directions
11. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer
12. Intra-arterial cisplatin and FUDR in advanced malignancies confined to the head and neck
13. A pilot study of intrarterial chemotherapy with cisplatin in locally advanced head and neck cancers
14. Intra-arterial continuous infusion of cisdiammine dichloroplatinum in untreated head and neck cancer patients
15. Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx
16. Stage III and IV squamous cell carcinoma of the mouth: Three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment
17. T1 and T2 lip cancer: A superselective method of facial arterial infusion therapy-preliminary experience
18. Phase I study of highly selective supradose cisplatin infusion for advanced head and neck cancer
19. A novel intra-arterial chemotherapeutic approach to squamous cell cancer of head and neck and anal canal using high dose Cremophor® EL-free paclitaxel/albumin nanoparticles (ABI-007)
20. Phase I study of cremphore-free, protein-stabilized, nanoparticle formulation of paclitaxel (ABI-007) in solid tumors
21. Molecular mechanisms of resistance to taxanes and therapeutic implications
22. Chemotherapy and radiation therapy for anal carcinoma
23. Combined chemoradiation therapy for anal cancer. A report of 56 cases
24. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma
25. The use of the angio-seal haemostatic puncture closure device in high risk patients
26. Pharmacologic rationale for regional drug delivery